Although it is crucial to evaluate PD-L1 expression accurately by IHC in clinical practice, the frequency of PD-L1 expression and its association with prognosis can vary due to several factors such as the antibody clone, the preparation of tissue samples, the evaluation system, tumor heterogeneity, and geographical differences of the recruited patients (15, 58). The gene discussed is CD274; the disease is neoplasm.